Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2862-2869

  Holden, Sylvia A ^a   Lan, Yan ^a   Pardo, Ana M ^a   Wesolowski, John S ^a   Gillies, Stephen D ^a   Gillies, Sylvia D ^a  

^a Lexigen Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GRAFT; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEWIS CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034814352     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy
2. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
3. Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody
4. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastasis
5. T cell memory against colon carcinoma is long-lived in the absence of antigen
6. Improved efficacy of mouse antibody-cytokine fusion proteins in syngeneic mouse tumor models is due to their reduced immunogenicity
7. Principles of combining biomodulators with cytotoxic agents in vivo
8. The immunological effects of taxanes
9. Effects of anticancer drugs on the immune system in humans
10. Chemoimmunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide
11. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications
12. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors
13. Therapy of advanced solid tumor in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells
14. Chemoimmunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide
15. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide
16. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors
17. Priming of the antitumor response promotes efficacy of interleukin-2 therapy
18. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide